Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosilate

Journal of Infection and Chemotherapy

Volumn 7, Issue 4, 2001, Pages 205-217

  Yamaguchi, K ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

In vitro antibacterial activity; L. pneumophila; S. pneumoniae; Structure activity relationship; Tosufloxacin tosilate

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLEROXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MINOCYCLINE; NAPHTHYRIDINE DERIVATIVE; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; TEMAFLOXACIN; TOSUFLOXACIN TOSILATE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CELL MEMBRANE TRANSPORT; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG SCREENING; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEGIONELLA PNEUMOPHILA; LUNG FIBROBLAST; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUROTOXICITY; NONHUMAN; POSTANTIBIOTIC EFFECT; RAT; REVIEW; SERRATIA MARCESCENS; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION;

EID: 0035698733     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560170015     Document Type: Review

References (33)

1. 1,8-Naphthyridinc derivatives. A new class of chemotherapeutic agents
2. Characteristics of antibacterial agents and their use: Quinolones
3. On the development of Ozex (tosufloxacin tosilate)
4. Pharmacokinetics of the pyridonecarboxylic acid antibacterial agent, tosufloxacin tosilate
5. Pyridonecarboxylic acids as antibacterial agents. Synthesis and structure-activity relationship of 1-aryl-6-(4-dimethylaminophenyl)-4-pyridone-3-carboxylic acids
6. Pyridonecarboxylic acids as antibacterial agents. Synthesis and structure-activity relationship of 1-(4-hydroxyphenyl)-6-substituted-4-pyridone-3-carboxylic acids
7. Pyridonecarboxylic acids as antibacterial agents. Synthesis and structure-activity relationship of 1-(4-fluorophenyl)-and 1-(2,4-difluorophenyl)-6-substituted-4-pyridone-3-carboxylic acids
8. Pyridonecarboxylic acids as antibacterial agents. Synthesis and structure-activity relationship of 7-amino-1-aryl-6-fluoro-4-quinolone-3-carboxylic acids
9. Pyridonecarboxylic acids as antibacterial agents. Synthesis and structure-activity relationship of 7-amino-6-fluoro-1-(fluorophenyl)-4-oxo-1,8-naphthylidine-3-carboxylic acids
10. Temafloxacin - Anatomy of a withdrawal
11. Method of in vitro determination of chlamydial susceptibility (minimum inhibitory concentration; MIC) to antimicrobial agents
12. In vitro and in vivo antibacterial activities of T-3262, a new synthetic antimicrobial agent
13. In vitro activity of T-3262, a new pyridonecarboxylic acid, against anaerobic bacteria
14. Respiratory infections due to Chlamydia - On Chlamydia pneumoniae infection in particular
15. In vitro activities of tosufloxacin and five quinolones against 1112 bacterial clinical isolates
16. Fundamental study on urogenital Chlamydial infection and antichlamydial chemotherapy
17. In vitro and in vivo antibacterial activity of T3262, a new pyridone carboxylic acid
18. Postantibiotic effect (PAE) of new quinolones
19. Intracellular activity of tosufloxacin (T-3262) against Salmonella enteritidis and ability to penetrate into tissue culture cells of human origin
20. In vitro and in vivo antibacterial activity of four newly developed quinolone agents against Legionella infection
21. Penetration of levofloxacin, a new quinolone antibacterial agent, into human neutrophils
22. Chemotherapy on Chlamydia pneumoniae infection
23. In vitro and in vivo antibacterial activity of new quinolones
24. Penicillin-resistant Streptococcus pneumoniae
25. Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India
26. Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae strains causing childhood infections in Bangladesh, 1993 to 1997
27. Low dosage and long treatment duration of β-lactam
28. Isolation of an ampicillin-resistant, non-βlactamase-producing strain of Haemophilus influenzae
29. Characterization of non-β-lactamase-mediated ampicillin resistance in Haemophilus influenzae
30. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study
31. Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin
32. The characteristics of infectious diseases